Jacob Johnson
Stock Analyst at Stephens & Co.
(3.43)
# 865
Out of 4,832 analysts
77
Total ratings
44.83%
Success rate
5.54%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $231.15 | +3.83% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $4.65 | +29.03% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $6.95 | -13.67% | 4 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $27.90 | +115.05% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $196.61 | +60.22% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $428.95 | +58.53% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $131.55 | +29.23% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $6.74 | -25.82% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $2.20 | +400.00% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $24.42 | +55.61% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $6.98 | +143.55% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $1.31 | +90.84% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $51.61 | +68.57% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $215.87 | +80.66% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $8.36 | +115.31% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $2.56 | +134.38% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $23.09 | +25.60% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $130 | $105.63 | +23.07% | 2 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $144.02 | +161.77% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $231.15
Upside: +3.83%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $4.65
Upside: +29.03%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $6.95
Upside: -13.67%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $27.90
Upside: +115.05%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $196.61
Upside: +60.22%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $428.95
Upside: +58.53%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $131.55
Upside: +29.23%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $6.74
Upside: -25.82%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.20
Upside: +400.00%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $24.42
Upside: +55.61%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $6.98
Upside: +143.55%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.31
Upside: +90.84%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $51.61
Upside: +68.57%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $215.87
Upside: +80.66%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $8.36
Upside: +115.31%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $2.56
Upside: +134.38%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $23.09
Upside: +25.60%
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $105.63
Upside: +23.07%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $144.02
Upside: +161.77%